Bortezomib Targets Sp Transcription Factors in Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Bortezomib is a key chemotherapeutic agent for multiple myeloma (MM) and other cancers.
• Specificity protein (Sp) transcription factors are often overexpressed in various cancer types.
• Understanding bortezomib's molecular targets is crucial for optimizing cancer treatment.

Purpose of the Study:

• To investigate the role of Sp1, Sp3, and Sp4 transcription factors in bortezomib's anti-cancer effects.
• To elucidate the molecular mechanism by which bortezomib downregulates Sp transcription factors.
• To confirm the functional significance of Sp transcription factor downregulation in MM cells.

Main Methods:

• Treatment of ANBL-6 and RPMI 8226 MM cells with bortezomib.
• Assessment of cell growth inhibition and apoptosis induction.
• Knockdown experiments for Sp1, Sp3, and Sp4 in MM cells.
• Analysis of caspase-8 and Fas-associated death domain activation.

Main Results:

• Bortezomib inhibited MM cell growth and induced apoptosis.
• Bortezomib treatment led to the downregulation of Sp1, Sp3, and Sp4 transcription factors.
• Individual knockdown of Sp1, Sp3, or Sp4 mimicked bortezomib's effects on cell growth and apoptosis.
• Bortezomib-induced downregulation of Sp transcription factors was mediated by caspase-8 activation.

Conclusions:

• Bortezomib's mechanism of action in MM involves the caspase-8-dependent downregulation of Sp1, Sp3, and Sp4.
• Targeting Sp transcription factors represents a significant pathway for bortezomib's anti-cancer activity.
• These findings support bortezomib's efficacy and provide insights into its therapeutic potential in MM and other cancers.